



**Universiteit  
Leiden**  
The Netherlands

## **Fetal and neonatal alloimmune thrombocytopenia: the proof of the pudding is in the eating**

Vos, T.W. de

### **Citation**

Vos, T. W. de. (2023, April 13). *Fetal and neonatal alloimmune thrombocytopenia: the proof of the pudding is in the eating*. Retrieved from <https://hdl.handle.net/1887/3593976>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3593976>

**Note:** To cite this publication please use the final published version (if applicable).

# **FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA:**

*the proof of the pudding is in the eating*

**THIJS W. DE VOS**

Fetal and neonatal alloimmune thrombocytopenia: the proof of the pudding is in the eating

© Copyright 2023, Thijs de Vos, Leiden, The Netherlands

All rights reserved. No part of this publication may be reproduced or transmitted in any form or any means, electronical or mechanical including photography or recording or any information storage or retrieval system without the written permission of the author.

The research described in this thesis was performed at the Willem-Alexander Children's Hospital, the Department of Obstetrics at the Leiden University Medical Center (Leiden), the Department of Experimental Immunohematology, the Department of Translational Immunohematology at Sanquin Research (Amsterdam) and Sanquin Diagnostic Services (Amsterdam).

ISBN: 978-94-6419-671-9

Layout and design:	Ilse Modder   <a href="http://www.ilsemodder.nl">www.ilsemodder.nl</a>
Cover painting:	Kimberley Innemee-de Vos
Cover design:	Ilse Modder   <a href="http://www.ilsemodder.nl">www.ilsemodder.nl</a>
Printing:	Gildeprint, Enschede, The Netherlands

The research described in this thesis was supported by Process and Product Development Diagnostic Services Sanquin (SQL/00034), Fonds Gezond Geboren (E50-03-LUMC) and Landsteiner Foundation for Blood Transfusion Research (1440).

Financial support for printing this thesis was kindly provided by, Naitbabies.org, Sanquin Research, Universitaire Bibliotheken Leiden, Immucor and Chiesi Pharmaceuticals B.V.

# **Fetal and neonatal alloimmune thrombocytopenia:**

*the proof of the pudding is in the eating*

Proefschrift

ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van de rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op donderdag 13 april 2023  
klokke 15:00 uur

door

Thijs Wilbert de Vos  
geboren te Den Haag  
in 1990

## PROMOTORES EN PROMOTIECOMMISSIE

**Promotores**                    prof. dr. M. de Haas  
    prof. dr. E. Lopriore

**Co-promotor**                dr. J.M.M. van Klink

**Leden promotiecommissie**    prof. dr. A.C. Lankester  
    prof. dr. H. Tiller            UiT the Arctic University of Norway  
    prof. dr. G. Bein              Justus-Liebig-University Giessen  
    prof. dr. M.N. Bekker        Universiteit Utrecht

*voor mijn lief*

*voor mijn ouders*

# TABLE OF CONTENTS

<b>Part one</b>	<b>Overview</b>	<b>11</b>
	General introduction and scope of the thesis	13
Chapter 1	Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia	23
<b>Part two</b>	<b>Natural history of HPA-1a mediated FNAIT</b>	<b>43</b>
Chapter 2	HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk	45
Chapter 3	The natural history of human platelet antigen (HPA)-1a alloimmunised pregnancies: a prospective observational cohort study	63
Chapter 4	Placental complement activation in fetal and neonatal alloimmune thrombocytopenia: an observational study	99
<b>Part three</b>	<b>Clinical relevance of HPA-5b antibodies</b>	<b>123</b>
Chapter 5	Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia	125
<b>Part four</b>	<b>Neonatal management</b>	<b>145</b>
Chapter 6	Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective cohort study	147
<b>Part five</b>	<b>Long-term outcome</b>	<b>177</b>
Chapter 7	Children newly diagnosed with fetal and neonatal alloimmune thrombocytopenia: neurodevelopmental outcome at school age	179
Chapter 8	Long-term neurodevelopmental outcome in children after antenatal intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia	199
<b>Part six</b>	<b>Cost effectiveness</b>	<b>219</b>
Chapter 9	Cost-utility analysis of screening of pregnant women for fetal neonatal alloimmune thrombocytopenia	221

<b>Part seven</b>	<b>Summary and discussion</b>	<b>247</b>
Chapter 10	General discussion and future perspectives	249
	Summary	287
	Nederlandse samenvatting	293
<b>Appendices</b>	List of abbreviations	<b>303</b>
	List of publications	307
	Curriculum vitae	311
	Dankwoord	313